Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter November 28, 2005

SELDI-TOF-MS proteomics of breast cancer

Charlotte H. Clarke, Julie A. Buckley and Eric T. Fung


The detection, diagnosis, and management of breast cancer rely on an integrated approach using clinical history, physical examination, imaging, and histopathology. The discovery and validation of novel biomarkers will aid the physician in more effectively achieving this integration. This review discusses efforts in surface-enhanced laser desorption/ionization (SELDI)-based proteomics to address various clinical questions surrounding breast cancer, including diagnosis, monitoring, and stratification for treatment. Emphasis is placed on examining how study design and execution influence the discovery and validation process, which is critical to the proper development of potential clinical tests.

Corresponding author: Eric T. Fung, Ciphergen Biosystems, Inc., Diagnostics Division, 6611 Dumbarton Circle, Fremont, CA 94555, USA Phone: +1-510-505-2242, Fax: +1-510-505-2101,


1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10–30.10.3322/canjclin.55.1.10Search in Google Scholar

2. Antman K, Shea S. Screening mammography under age 50. J Am Med Assoc 1999; 281:1470–2.10.1001/jama.281.16.1470Search in Google Scholar

3. Lumachi F, Basso SM. Serum tumor markers in patients with breast cancer. Expert Rev Anticancer Ther 2004; 4:921–31.10.1586/14737140.4.5.921Search in Google Scholar

4. Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res 2004; 6:109–18.10.1186/bcr777Search in Google Scholar

5. Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 2005; 65:767–79.Search in Google Scholar

6. Somiari RI, Somiari S, Russell S, Shriver CD. Proteomics of breast carcinoma. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 815:215–25.10.1016/j.jchromb.2004.11.012Search in Google Scholar

7. Celis JE, Gromov P, Cabezon T, Moreira JM, Ambartsumian N, Sandelin K, et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics 2004; 3:327–44.10.1074/mcp.M400009-MCP200Search in Google Scholar

8. Stein RC, Zvelebil MJ. The application of 2D gel-based proteomics methods to the study of breast cancer. J Mammary Gland Biol Neoplasia 2002; 7:385–93.10.1023/A:1024034031472Search in Google Scholar

9. Hathout Y, Gehrmann ML, Chertov A, Fenselau C. Proteomic phenotyping: metastatic and invasive breast cancer. Cancer Lett 2004; 210:245–53.10.1016/j.canlet.2004.01.019Search in Google Scholar

10. Yates JR III. Mass spectral analysis in proteomics. Annu Rev Biophys Biomol Struct 2004; 33:297–316.10.1146/annurev.biophys.33.111502.082538Search in Google Scholar

11. Rodland KD. Proteomics and cancer diagnosis: the potential of mass spectrometry. Clin Biochem 2004; 37:579–83.10.1016/j.clinbiochem.2004.05.011Search in Google Scholar

12. Veenstra TD, Prieto DA, Conrads TP. Proteomic patterns for early cancer detection. Drug Discov Today 2004; 9:889–97.10.1016/S1359-6446(04)03246-5Search in Google Scholar

13. Espina V, Dettloff KA, Cowherd S, Petricoin EF III, Liotta LA. Use of proteomic analysis to monitor responses to biological therapies. Expert Opin Biol Ther 2004; 4:83–93.10.1517/14712598.4.1.83Search in Google Scholar

14. Tang N, Tornatore P, Weinberger SR. Current developments in SELDI affinity technology. Mass Spectrom Rev 2004; 23:34–44.10.1002/mas.10066Search in Google Scholar

15. Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002; 292:587–92.10.1006/bbrc.2002.6678Search in Google Scholar

16. Oehr P. Proteomics as a tool for detection of nuclear matrix proteins and new biomarkers for screening of early tumors stage. Anticancer Res 2003; 23:805–12.Search in Google Scholar

17. Fung ET, Enderwick C. ProteinChip clinical proteomics: computational challenges and solutions. Biotechniques 2002; 32(Suppl):34–41.10.2144/mar0205Search in Google Scholar

18. Kearney P, Thibault P. Bioinformatics meets proteomics – bridging the gap between mass spectrometry data analysis and cell biology. J Bioinform Comput Biol 2003; 1:183–200.10.1142/S021972000300023XSearch in Google Scholar

19. White CN, Chan DW, Zhang Z. Bioinformatics strategies for proteomic profiling. Clin Biochem 2004; 37:636–41.10.1016/j.clinbiochem.2004.05.004Search in Google Scholar

20. Coombes KR, Morris JS, Hu J, Edmonson SR, Baggerly KA. Serum proteomics profiling – a young technology begins to mature. Nat Biotechnol 2005; 23:291–2.10.1038/nbt0305-291Search in Google Scholar

21. Hu J, Coombes KR, Morris JS, Baggerly KA. The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. Brief Funct Genomic Proteomic 2005; 3:322–31.10.1093/bfgp/3.4.322Search in Google Scholar

22. White CN, Zhang Z, Chan DW. Quality control for SELDI analysis. Clin Chem Lab Med 2005; 43:125–6.Search in Google Scholar

23. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004; 96:353–6.10.1093/jnci/djh056Search in Google Scholar

24. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64:5882–90.10.1158/0008-5472.CAN-04-0746Search in Google Scholar

25. Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005; 51:102–12.10.1373/clinchem.2004.038950Search in Google Scholar

26. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004; 4:309–14.10.1038/nrc1322Search in Google Scholar

27. Vlahou A, Laronga C, Wilson L, Gregory B, Fournier K, McGaughey D, et al. A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 2003; 4:203–9.10.1016/S1526-8209(11)70627-9Search in Google Scholar

28. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48:1296–304.10.1093/clinchem/48.8.1296Search in Google Scholar

29. Donegan WL. Evaluation of a palpable breast mass. N Engl J Med 1992; 327:937–42.10.1056/NEJM199209243271307Search in Google Scholar

30. Hu Y, Zhang SZ, Yu JK, Liu J, Zheng S, Hu X. [Diagnostic application of serum protein pattern and artificial neural network software in breast cancer.]. Ai Zheng 2005; 24:67–71.Search in Google Scholar

31. Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen J, Kuerer HM, et al. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 2004; 100:1814–22.10.1002/cncr.20203Search in Google Scholar

32. Caputo E, Lombardi ML, Luongo V, Moharram R, Tornatore P, Pirozzi G, et al. Peptide profiling in epithelial tumor plasma by the emerging proteomic techniques. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 819:59–66.10.1016/j.jchromb.2005.01.022Search in Google Scholar

33. Fung ET, Yip TT, Lomas L, Wang Z, Yip C, Meng XY, et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 2005; 115:783–9.10.1002/ijc.20928Search in Google Scholar

34. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302:643–6.10.1126/science.1088759Search in Google Scholar

35. Laronga C, Becker S, Watson P, Gregory B, Cazares L, Lynch H, et al. SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis Markers 2003; 19:229–38.10.1155/2004/759530Search in Google Scholar

36. Becker S, Cazares LH, Watson P, Lynch H, Semmes OJ, Drake RR, et al. Surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol 2004; 11:907–14.10.1245/ASO.2004.03.557Search in Google Scholar

37. Heike Y, Hosokawa M, Osumi S, Fujii D, Aogi K, Takigawa N, et al. Identification of serum proteins related to adverse effects induced by docetaxel infusion from protein expression profiles of serum using SELDI Protein-Chip system. Anticancer Res 2005; 25:1197–203.Search in Google Scholar

38. Khan SA. The role of ductal lavage in the management of women at high risk for breast carcinoma. Curr Treat Options Oncol 2004; 5:145–51.10.1007/s11864-004-0046-ySearch in Google Scholar

39. Petricoin EE, Paweletz CP, Liotta LA. Clinical applications of proteomics: proteomic pattern diagnostics. J Mammary Gland Biol Neoplasia 2002; 7:433–40.10.1023/A:1024042200521Search in Google Scholar

40. Paweletz CP, Trock B, Pennanen M, Tsangaris T, Magnant C, Liotta LA, et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 2001; 17:301–7.10.1155/2001/674959Search in Google Scholar

41. Kuerer HM, Coombes KR, Chen JN, Xiao L, Clarke C, Fritsche H, et al. Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer. Surgery 2004; 136:1061–9.10.1016/j.surg.2004.04.011Search in Google Scholar

42. Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, et al. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat 2005; 89:149–57.10.1007/s10549-004-1710-4Search in Google Scholar

43. Sauter ER, Zhu W, Fan XJ, Wassell RP, Chervoneva I, Du Bois GC. Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Br J Cancer 2002; 86:1440–3.10.1038/sj.bjc.6600285Search in Google Scholar

44. Sauter ER, Shan S, Hewett JE, Speckman P, Du Bois GC. Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS. Int J Cancer 2005; 114:791–6.10.1002/ijc.20742Search in Google Scholar

45. Mendrinos S, Nolen JD, Styblo T, Carlson G, Pohl J, Lewis M, et al. Cytologic findings and protein expression profiles associated with ductal carcinoma of the breast in ductal lavage specimens using surface-enhanced laser desorption and ionization-time of flight mass spectrometry. Cancer 2005; 105:178–83.10.1002/cncr.21052Search in Google Scholar

46. Fowler LJ, Lovell MO, Izbicka E. Fine-needle aspiration in PreservCyt: a novel and reproducible method for possible ancillary proteomic pattern expression of breast neoplasms by SELDI-TOF. Mod Pathol 2004; 17:1012–20.10.1038/modpathol.3800116Search in Google Scholar

47. Coombes KR, Fritsche HA Jr, Clarke C, Chen JN, Baggerly KA, Morris JS, et al. Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. Clin Chem 2003; 49:1615–23.10.1373/49.10.1615Search in Google Scholar

48. Mian S, Ball G, Hornbuckle J, Holding F, Carmichael J, Ellis I, et al. A prototype methodology combining surface-enhanced laser desorption/ionization protein chip technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer cell lines exposed to Paclitaxel and Doxorubicin under in vitro conditions. Proteomics 2003; 3:1725–37.10.1002/pmic.200300526Search in Google Scholar

49. Carter D, Douglass JF, Cornellison CD, Retter MW, Johnson JC, Bennington AA, et al. Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer. Biochemistry 2002; 41:6714–22.10.1021/bi0159884Search in Google Scholar

50. Euhus DM. Understanding mathematical models for breast cancer risk assessment and counseling. Breast J 2001; 7:224–32.10.1046/j.1524-4741.2001.20012.xSearch in Google Scholar

51. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351:427–37.10.1056/NEJMoa031759Search in Google Scholar

52. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999–2009.10.1056/NEJMoa021967Search in Google Scholar

53. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817–26.10.1056/NEJMoa041588Search in Google Scholar

54. Celis JE, Gromov P, Gromova I, Moreira JM, Cabezon T, Ambartsumian N, et al. Integrating proteomic and functional genomic technologies in discovery-driven translational breast cancer research. Mol Cell Proteomics 2003; 2:369–77.10.1074/mcp.R300007-MCP200Search in Google Scholar

55. Celis JE, Moreira JM, Gromova I, Cabezon T, Ralfkiaer U, Guldberg P, et al. Towards discovery-driven translational research in breast cancer. FEBS J 2005; 272:2–15.10.1111/j.1432-1033.2004.04418.xSearch in Google Scholar

Received: 2005-6-29
Accepted: 2005-10-10
Published Online: 2005-11-28
Published in Print: 2005-12-1

©2005 by Walter de Gruyter Berlin New York